StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

The company has a market cap of $24.33 million, a PE ratio of -0.25 and a beta of 0.41. The business has a 50 day moving average of $15.19 and a two-hundred day moving average of $13.17. Cara Therapeutics has a twelve month low of $8.13 and a twelve month high of $31.32.

Institutional Investors Weigh In On Cara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the last quarter. Curi RMB Capital LLC bought a new stake in shares of Cara Therapeutics in the fourth quarter worth about $277,000. Shay Capital LLC purchased a new stake in shares of Cara Therapeutics in the fourth quarter worth about $524,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Cara Therapeutics in the fourth quarter worth about $953,000. Institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.